 |
| (사진= 연합뉴스) |
[Alpha Biz=(Chicago) Reporter Paul Lee] Celltrion achieved record-high sales of more than 2 trillion won last year due to strong biosimilar business.
Celltrion announced on the 3rd that it achieved consolidated sales of 2.2839 trillion won, operating profit of 647.1 billion won and operating profit ratio of 28.3% in 2022. Sales rose 20.6% year-on-year, marking the largest annual sales ever.
In the fourth quarter of last year, sales of the biosimilar business grew more than 50% year-on-year despite a drop in sales related to COVID-19 and consignment production (CMO) with sales of KRW 510.6 billion and operating profit of KRW 100.6 billion.
Operating profit fell in part compared to the previous year, but it maintained an annual operating profit ratio of 30%, excluding temporary costs related to diagnostic kits. In addition, the diagnostic kit evaluation loss was completed by the fourth quarter.
Celltrion plans to continue to grow this year by securing future new growth engines such as △ launch of new biosimilar products △ Biosimilar formulation and device differentiation △ development of bio-new drugs.
AlphaBIZ 폴리(hoondork1977@alphabiz.co.kr)
